<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName journalpublishing.dtd?>
<?SourceDTD.Version 2.3?>
<?ConverterInfo.XSLTName nlm2jats3.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Front Cell Dev Biol</journal-id>
    <journal-id journal-id-type="iso-abbrev">Front Cell Dev Biol</journal-id>
    <journal-id journal-id-type="publisher-id">Front. Cell Dev. Biol.</journal-id>
    <journal-title-group>
      <journal-title>Frontiers in Cell and Developmental Biology</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2296-634X</issn>
    <publisher>
      <publisher-name>Frontiers Media S.A.</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">8335569</article-id>
    <article-id pub-id-type="doi">10.3389/fcell.2021.715275</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Cell and Developmental Biology</subject>
        <subj-group>
          <subject>Original Research</subject>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Identification of Somatic Mutation-Driven Immune Cells by Integrating Genomic and Transcriptome Data</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Jiang</surname>
          <given-names>Ying</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <xref ref-type="author-notes" rid="fn002">
          <sup>†</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/981074/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zheng</surname>
          <given-names>Baotong</given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
          <sup>2</sup>
        </xref>
        <xref ref-type="author-notes" rid="fn002">
          <sup>†</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yang</surname>
          <given-names>Yang</given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
          <sup>2</sup>
        </xref>
        <xref ref-type="author-notes" rid="fn002">
          <sup>†</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Xiangmei</given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
          <sup>2</sup>
        </xref>
        <xref ref-type="author-notes" rid="fn002">
          <sup>†</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Han</surname>
          <given-names>Junwei</given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
          <sup>2</sup>
        </xref>
        <xref ref-type="corresp" rid="c001">
          <sup>*</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/291330/overview"/>
      </contrib>
    </contrib-group>
    <aff id="aff1"><sup>1</sup><institution>College of Basic Medical Science, Heilongjiang University of Chinese Medicine</institution>, <addr-line>Harbin</addr-line>, <country>China</country></aff>
    <aff id="aff2"><sup>2</sup><institution>College of Bioinformatics Science and Technology, Harbin Medical University</institution>, <addr-line>Harbin</addr-line>, <country>China</country></aff>
    <author-notes>
      <fn fn-type="edited-by">
        <p>Edited by: Lei Deng, Central South University, China</p>
      </fn>
      <fn fn-type="edited-by">
        <p>Reviewed by: Jing Li, Fujian Medical University, China; Juan Wang, Inner Mongolia University, China</p>
      </fn>
      <corresp id="c001">*Correspondence: Junwei Han, <email>hanjunwei1981@163.com</email></corresp>
      <fn fn-type="other" id="fn002">
        <p><sup>†</sup>These authors have contributed equally to this work</p>
      </fn>
      <fn fn-type="other" id="fn004">
        <p>This article was submitted to Molecular and Cellular Pathology, a section of the journal Frontiers in Cell and Developmental Biology</p>
      </fn>
    </author-notes>
    <pub-date pub-type="epub">
      <day>21</day>
      <month>7</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2021</year>
    </pub-date>
    <volume>9</volume>
    <elocation-id>715275</elocation-id>
    <history>
      <date date-type="received">
        <day>26</day>
        <month>5</month>
        <year>2021</year>
      </date>
      <date date-type="accepted">
        <day>25</day>
        <month>6</month>
        <year>2021</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Copyright © 2021 Jiang, Zheng, Yang, Li and Han.</copyright-statement>
      <copyright-year>2021</copyright-year>
      <copyright-holder>Jiang, Zheng, Yang, Li and Han</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
      </license>
    </permissions>
    <abstract>
      <p>Tumor somatic mutations in protein-coding regions may generate neoantigens which may trigger antitumor immune cell response. Increasing evidence supports that immune cell response may profoundly influence tumor progression. However, there are no calculated tools to systematically identify immune cells driven by specific somatic mutations. It is urgent to develop a calculated method to comprehensively detect tumor-infiltrating immune cells driven by the specific somatic mutations in cancer. We developed a novel software package (SMDIC) that enables the automated identification of somatic mutation-driven immune cell. SMDIC provides a novel pipeline to discover mutation-specific immune cells by integrating genomic and transcriptome data. The operation modes include inference of the relative abundance matrix of tumor-infiltrating immune cells, detection of differential abundance immune cells with respect to the gene mutation status, conversion of the abundance matrix of significantly dysregulated cells into two binary matrices (one for upregulated and one for downregulated cells), identification of somatic mutation-driven immune cells by comparing the gene mutation status with each immune cell in the binary matrices across all samples, and visualization of immune cell abundance of samples in different mutation status for each gene. SMDIC provides a user-friendly tool to identify somatic mutation-specific immune cell response. SMDIC may contribute to understand the mechanisms underlying anticancer immune response and find targets for cancer immunotherapy. The SMDIC was implemented as an R-based tool which was freely available from the CRAN website <ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=SMDIC">https://CRAN.R-project.org/package=SMDIC</ext-link>.</p>
    </abstract>
    <kwd-group>
      <kwd>multi-omics data</kwd>
      <kwd>somatic mutations</kwd>
      <kwd>tumor-infiltrating immune cells</kwd>
      <kwd>tumor microenvironment</kwd>
      <kwd>gene expression</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source id="cn001">Natural Science Foundation of Heilongjiang Province<named-content content-type="fundref-id">10.13039/501100005046</named-content></funding-source>
      </award-group>
    </funding-group>
    <counts>
      <fig-count count="6"/>
      <table-count count="2"/>
      <equation-count count="1"/>
      <ref-count count="29"/>
      <page-count count="10"/>
      <word-count count="0"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec id="S1">
    <title>Introduction</title>
    <p>Tumor generally harbors somatic mutations, some of which in protein-coding regions may generate neoantigens which may trigger antitumor immune cell response in the tumor microenvironment (TME) (<xref rid="B29" ref-type="bibr">Yang et al., 2019</xref>). The mutation-reactive immune cells are usually found infiltrating into solid tumors (<xref rid="B24" ref-type="bibr">Robbins et al., 2013</xref>), and they profoundly influence tumor initiation, progression, metastasis, and treatment response (<xref rid="B6" ref-type="bibr">Chen and Mellman, 2017</xref>). For example, <xref rid="B27" ref-type="bibr">Tran et al. (2014)</xref> identify erbb2 interacting protein (ERBB2IP) mutation-specific CD4<sup>+</sup> T (TH1) cells in a patient with metastatic cholangiocarcinoma and demonstrate that the ERBB2IP mutated-specific TH1 cell response can be used to mediate regression of metastatic epithelial cancer. Therefore, identifying mutation-specific immune cell response will illustrate the mechanisms underlying the anticancer immune response and might help to find targets for cancer immunotherapy (<xref rid="B29" ref-type="bibr">Yang et al., 2019</xref>). However, there are very few calculated tools that could comprehensively identify which immune cells are triggered by which mutations. Thus, it is urgent to develop a calculated method to comprehensively detect tumor-infiltrating immune cells driven by the specific somatic mutations in cancer. Recently, a number of computational approaches have been developed for quantifying tumor-infiltrating immune cells using tumor bulk gene expression data (<xref rid="B20" ref-type="bibr">Newman et al., 2015</xref>; <xref rid="B25" ref-type="bibr">Senbabaoglu et al., 2016</xref>; <xref rid="B2" ref-type="bibr">Aran et al., 2017</xref>). This will help to examine the correlation among somatic mutations and immune cells by using high-throughput sequencing data, for example whole-exome sequencing and RNA-seq.</p>
    <p>Here, we developed a novel software package, SMDIC, to identify immune cells driven by specific somatic mutations by integrating genomic and transcriptome data, which is available at <ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=SMDIC">https://CRAN.R-project.org/package=SMDIC</ext-link>. SMDIC also provides visualization of the relative abundance of identified immune cells in the gene mutation status using heat maps, as well as the waterfall plot of mutation genes correlated with immune cells and mutually exclusive and co-occurring plot. We used the Genomic Data Commons (GDC) TCGA breast cancer somatic mutation and expression data to show the applications of the package and the visualization of the results. The results showed that SMDIC could effectively identify immune cells which may be driven by the specific somatic mutation genes, with strong robustness.</p>
  </sec>
  <sec sec-type="materials|methods" id="S2">
    <title>Materials and Methods</title>
    <p>SMDIC has three main functions (<xref ref-type="fig" rid="F1">Figure 1</xref>): (a) inferring the relative abundance matrix of tumor-infiltrating immune cells, (b) detecting differential abundance immune cells with respect to a particular gene mutation status and converting the abundance matrix of significantly dysregulated immune cells into two binary matrices (one for upregulated and one for downregulated cells), and (c) identifying somatic mutation-driven immune cells by comparing the gene mutation status with each immune cell in the binary matrices across all samples.</p>
    <fig id="F1" position="float">
      <label>FIGURE 1</label>
      <caption>
        <p>Flow diagram of SMDIC. <bold>(A)</bold> Inference of the relative abundance matrix of immune cells; <bold>(B)</bold> Detection of differential abundance immune cells with respect to the gene mutation status; <bold>(C)</bold> Identification of significant immune cells associated with somatic mutation.</p>
      </caption>
      <graphic xlink:href="fcell-09-715275-g001"/>
    </fig>
    <sec id="S2.SS1">
      <title>Inference of the Relative Abundance Matrix of Immune Cells</title>
      <p>Recently, various computational approaches have been developed for quantifying tumor-infiltrating immune cells from gene expression data of human bulk tumors. The SMDIC package provides three methods for estimating the relative infiltration abundance of different cell types in the tumor microenvironment (TME), namely, xCell (<xref rid="B2" ref-type="bibr">Aran et al., 2017</xref>), ssGSEA estimated method using the signatures of (<xref rid="B5" ref-type="bibr">Bindea et al., 2013</xref>; <xref rid="B25" ref-type="bibr">Senbabaoglu et al., 2016</xref>), and CIBERSORT (<xref rid="B20" ref-type="bibr">Newman et al., 2015</xref>). Through these methods, the relative abundance matrix of immune cells is inferred with cells as rows and samples as columns (<xref ref-type="fig" rid="F1">Figure 1A</xref>). In the package, the default method is xCell, which estimates abundances of 64 cell types including adaptive and innate immunity cells, hematopoietic progenitors, epithelial cells, and extracellular matrix cells (<xref rid="B2" ref-type="bibr">Aran et al., 2017</xref>). The users can choose the method they are interested in.</p>
    </sec>
    <sec id="S2.SS2">
      <title>Detection of Differential Abundance Immune Cells With Respect to the Gene Mutation Status</title>
      <p>The somatic mutation data used in the package are the mutation annotation file (MAF) format. We extract the non-silent somatic mutations (non-sense mutation, missense mutation, frame-shift indels, splice site, non-stop mutation, translation start site, inframe indels) in protein-coding regions and built a binary mutations matrix, in which 1 represents any mutation occurs in a particular gene in a particular sample; otherwise, the element is 0. The genes with a particular mutation frequency greater than a given threshold value are retained for the following analysis. Then, for a given mutation gene, the significance analysis of microarrays (SAM) method (<xref rid="B28" ref-type="bibr">Tusher et al., 2001</xref>) is used to detect differential abundance immune cells with respect to the mutation status (defined by binary mutation vector) across all the samples. With a false discovery rate (FDR) &lt; 0.05 in SAM, the immune cells were deemed as significantly dysregulated between mutation and non-mutation samples and were considered to be correlated with the gene mutation status. Then, the abundance matrix elements of significantly dysregulated immune cells are converted to <italic>z</italic>-scores by row. For the upregulated (or downregulated) immune cells, any element with a <italic>z</italic>-score &gt; 2.0 (or ≤ 2.0) is assigned with 1; otherwise, the element is 0 (<xref ref-type="fig" rid="F1">Figure 1B</xref>). Thus, we obtain two binary abundance matrices for upregulated and downregulated immune cells, respectively.</p>
    </sec>
    <sec id="S2.SS3">
      <title>Identification of Somatic Mutation-Driven Immune Cells</title>
      <p>For a particular mutation gene, we compare the binary mutation vector with each binary cell abundance vector in the upregulated or downregulated immune cell–matrix, respectively, and a 2 × 2 contingency table is constructed. The Fisher’s exact test is applied to recover the cells that had drastic mutation-correlated upregulated or downregulated response (<xref ref-type="fig" rid="F1">Figure 1C</xref>). This process is repeated for each immune cell in the binary abundance matrices. To correct for multiple comparisons, we adjust the exact test <italic>p</italic>-values by using the FDR method proposed by <xref rid="B3" ref-type="bibr">Benjamini and Hochberg (1995)</xref>. The immune cells with the default FDR &lt; 0.05 are deemed as statistically significant mutation-correlated and may be driven by the somatic mutation. We repeat the above process for each mutated gene.</p>
      <p>To further test if the somatic mutation-specific immune cells are associated with the prognosis of tumor patients, we constructed a signature by using immune cells driven by a particular gene mutation. The immune cell risk score was calculated with a prognostic score model for each patient based on the abundances of cells. The model is as follows:</p>
      <disp-formula id="S2.E1">
        <label>(1)</label>
        <mml:math id="M1">
          <mml:mrow>
            <mml:mrow>
              <mml:mi>R</mml:mi>
              <mml:mo>⁢</mml:mo>
              <mml:mi>i</mml:mi>
              <mml:mo>⁢</mml:mo>
              <mml:mi>s</mml:mi>
              <mml:mo>⁢</mml:mo>
              <mml:mpadded width="+5pt">
                <mml:mi>k</mml:mi>
              </mml:mpadded>
              <mml:mo>⁢</mml:mo>
              <mml:mi>s</mml:mi>
              <mml:mo>⁢</mml:mo>
              <mml:mi>c</mml:mi>
              <mml:mo>⁢</mml:mo>
              <mml:mi>o</mml:mi>
              <mml:mo>⁢</mml:mo>
              <mml:mi>r</mml:mi>
              <mml:mo>⁢</mml:mo>
              <mml:mi>e</mml:mi>
            </mml:mrow>
            <mml:mo>=</mml:mo>
            <mml:mrow>
              <mml:munder>
                <mml:mo largeop="true" movablelimits="false" symmetric="true">∑</mml:mo>
                <mml:mrow>
                  <mml:mi>k</mml:mi>
                  <mml:mo>∈</mml:mo>
                  <mml:mi>S</mml:mi>
                </mml:mrow>
              </mml:munder>
              <mml:mrow>
                <mml:msub>
                  <mml:mi mathvariant="normal">β</mml:mi>
                  <mml:mi>k</mml:mi>
                </mml:msub>
                <mml:mo>⁢</mml:mo>
                <mml:msub>
                  <mml:mi>a</mml:mi>
                  <mml:mi>k</mml:mi>
                </mml:msub>
              </mml:mrow>
            </mml:mrow>
          </mml:mrow>
        </mml:math>
      </disp-formula>
      <p>where <italic>S</italic> is the set of cells correlated with a particular gene mutation, <italic>a</italic><sub><italic>k</italic></sub> is the abundance of cell <italic>k</italic>, and <italic>β<sub><italic>k</italic></sub></italic> is the regression coefficient of a multivariate Cox proportional hazard regression model estimated on <italic>a</italic><sub><italic>k</italic></sub> and the overall survival data. According to the median of risk scores of the immune cell signature, patients are classified into high-risk and low-risk groups.</p>
    </sec>
  </sec>
  <sec id="S3">
    <title>Results</title>
    <p>We selected the GDC TCGA Breast Cancer (BRCA) data cohorts<sup><xref ref-type="fn" rid="footnote1">1</xref></sup> as examples to explain the application of the SMDIC package. We downloaded the MAF file (derived from VarScan 2) from the GDC data portal, which is obtained from TCGA whole-exome sequencing (WES) data. Meantime, the RNA-seq FPKM gene expression data and the associated clinical data were also downloaded. These data have been deposited in <xref ref-type="supplementary-material" rid="DS1">Supplementary Data</xref>.</p>
    <sec id="S3.SS1">
      <title>Identification of Immune Cells Driven by Somatic Mutations in Breast Cancer</title>
      <p>For the expression data, log-transformed FPKM expression values were used and were inputted into the “exp2cell” function for inferring the relative abundance matrix of infiltrated immune cells. The “exp2cell” function provides three methods for inferring the cell abundance matrix, namely, xCell (<xref rid="B2" ref-type="bibr">Aran et al., 2017</xref>), ssGSEA estimated method using the immune signatures of <xref rid="B5" ref-type="bibr">Bindea et al.(2013</xref>; <xref rid="B25" ref-type="bibr">Senbabaoglu et al., 2016</xref>), and CIBERSORT (<xref rid="B20" ref-type="bibr">Newman et al., 2015</xref>). The users can use the argument “method” to select the method they are interested in. The default argument is “xCell” method. Thus, a cell abundance matrix with 64 cells and 974 samples was obtained.</p>
      <p>We then extracted the non-silent somatic mutations (non-sense mutation, missense mutation, frame-shift indels, splice site, non-stop mutation, translation start site, inframe indels) in protein-coding regions from the MAF file and built a binary mutation matrix, in which 1 represents any mutation occurs in a particular gene in a particular sample; otherwise, the element is 0. The “maf2matrix” function was used to implement this process. Alternatively, the users can directly input a binary mutation matrix which may not be derived from the MAF file. This will increase the usability of our package. With a given mutation frequency threshold (the default value is 1%), a binary matrix with 821 mutations and 974 samples was obtained.</p>
      <p>In the SMDIC package, the “mutcorcell” function is implemented to identify somatic mutation-specific immune cell response by inputting the abundance matrix of immune cells and binary mutations matrix. This function firstly detects differential abundance immune cells with respect to a particular gene mutation status with the SAM method (<xref rid="B28" ref-type="bibr">Tusher et al., 2001</xref>). The immune cells with the default FDR &lt; 0.05 in SAM are deemed as significantly dysregulated between mutation and non-mutation samples and are considered to be correlated with the gene mutation status. The significantly dysregulated immune cells are extracted and their abundance matrix elements are converted to <italic>z</italic>-scores by row. Then, the <italic>z</italic>-score abundance matrix is converted to two binary abundance matrices for upregulated and downregulated immune cells, respectively. Specifically, for the upregulated (or downregulated) immune cells, any element with a <italic>z</italic>-score &gt; 2.0 (or ≤ 2.0) is assigned with 1; otherwise, the element is 0 (<xref ref-type="fig" rid="F1">Figure 1B</xref>). Finally, for a particular mutation gene, the binary mutation vector is compared with each binary cell abundance vector in the upregulated and downregulated cell matrices, respectively, and a 2 × 2 contingency table is constructed. Moreover, the Fisher’s exact test is applied to recover the cells that had drastic mutation-correlated upregulated or downregulated response. This process is repeated for each immune cell in the binary abundance matrices. To correct for multiple comparisons, the exact test <italic>p</italic>-values are adjusted by using the FDR method (<xref rid="B3" ref-type="bibr">Benjamini and Hochberg, 1995</xref>), and the immune cells with the default FDR &lt; 0.05 are deemed as statistically significant mutation-correlated and may be driven by the somatic mutation. The above process is repeated for each mutated gene.</p>
      <p>The “mutcorcell” function will output the summary results of somatic mutation-driven immune cells and the detailed information of immune cells for each mutation, which are used as input data for the visualization functions. The detailed commands are listed in the <xref ref-type="supplementary-material" rid="SM1">Supplementary Material</xref>, and the GDC TCGA breast cancer datasets (mutation data, gene expression data, and survival data of patients) are stored in <xref ref-type="supplementary-material" rid="DS1">Supplementary Data</xref>. The summary results of immune cells driven by somatic mutation genes are listed in <xref rid="T1" ref-type="table">Table 1</xref>, and many of them have been reported in the recent literature. For example, regulatory T cells (Treg) have been found to be associated with a high mutation rate of TP53 genes in breast cancer (<xref rid="B22" ref-type="bibr">Oshi et al., 2020</xref>). The TP53 mutant has been identified to be associated with a higher expression of cytotoxic T-cell lymphocytes, natural killer (NK) cells, and Th1 genes characteristic of a proinflammatory immune cell signature (<xref rid="B1" ref-type="bibr">Agupitan et al., 2020</xref>). E-cadherin (CDH1) has been reported to target platelet endothelial cell adhesion molecule-1 (PECAM-1) for ubiquitination and degradation in endothelial cells (<xref rid="B18" ref-type="bibr">Liu et al., 2020</xref>), whose mutation may regulate endothelial cell homeostasis. Our results are consistent with these findings, and SMDIC could also identify some additional immune cells driven by these mutations, which may provide some new biological insights.</p>
      <table-wrap id="T1" position="float">
        <label>TABLE 1</label>
        <caption>
          <p>The summary results of immune cells driven by somatic mutation genes.</p>
        </caption>
        <table frame="hsides" rules="groups" cellspacing="5" cellpadding="5">
          <thead>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Gene</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Cells</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Cell count</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Mutation rate</td>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>TP53</italic>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">Astrocytes, CD8<sup>+</sup> naive T cells, CD8<sup>+</sup> Tem, DC, epithelial cells, keratinocytes, macrophages, macrophages M1, melanocytes, NK cells, pDC, pericytes, plasma cells, pro-B cells, sebocytes, Tgd cells, Th1 cells, Th2 cells, Tregs</td>
              <td valign="top" align="center" rowspan="1" colspan="1">19</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.34</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>CDH1</italic>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">Adipocytes, CD4<sup>+</sup> Tcm, chondrocytes, CMP, endothelial cells, fibroblasts, HSC, ly endothelial cells, megakaryocytes, mesangial cells, mv endothelial cells, NKT</td>
              <td valign="top" align="center" rowspan="1" colspan="1">12</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.13</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>NBPF14</italic>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">CD8<sup>+</sup> Tem, DC, iDC, keratinocytes, pro-B cells, sebocytes</td>
              <td valign="top" align="center" rowspan="1" colspan="1">6</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.013</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>OBSCN</italic>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">Epithelial cells, keratinocytes, pro-B cells, sebocytes, Th1 cells</td>
              <td valign="top" align="center" rowspan="1" colspan="1">5</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.030</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>NF1</italic>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">aDC, B cells, memory B cells, pDC, plasma cells</td>
              <td valign="top" align="center" rowspan="1" colspan="1">5</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.037</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>ANKRD30A</italic>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">Keratinocytes, sebocytes, Th1 cells, Th2 cells</td>
              <td valign="top" align="center" rowspan="1" colspan="1">4</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.015</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>ARAP3</italic>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">CD8<sup>+</sup> naive T cells, NK cells, preadipocytes, Th1 cells</td>
              <td valign="top" align="center" rowspan="1" colspan="1">4</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.010</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>NOS1</italic>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">CD4<sup>+</sup> Tem, CD8<sup>+</sup> T cells, CD8<sup>+</sup> Tcm, pDC</td>
              <td valign="top" align="center" rowspan="1" colspan="1">4</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.012</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>PCDH19</italic>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">CD4<sup>+</sup> memory T cells, CD4<sup>+</sup> T cells, CD8<sup>+</sup> Tem, NK cells</td>
              <td valign="top" align="center" rowspan="1" colspan="1">4</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.018</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>KCNA4</italic>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">CD8<sup>+</sup> T cells, CD8<sup>+</sup> Tcm, NK cells, pDC</td>
              <td valign="top" align="center" rowspan="1" colspan="1">4</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.011</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>SCN5A</italic>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">CD8<sup>+</sup> T cells, CD8<sup>+</sup> Tcm, plasma cells</td>
              <td valign="top" align="center" rowspan="1" colspan="1">3</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.013</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>ACTN2</italic>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">NK cells, pDC, Th2 cells</td>
              <td valign="top" align="center" rowspan="1" colspan="1">3</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.011</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>FBXW7</italic>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">MEP, Th1 cells, Th2 cells</td>
              <td valign="top" align="center" rowspan="1" colspan="1">3</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.016</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>TRPS1</italic>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">CD4<sup>+</sup> Tem, MSC, skeletal muscle</td>
              <td valign="top" align="center" rowspan="1" colspan="1">3</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.011</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <attrib>
            <italic>
              <italic>The mutation genes correlated at least three significant cells are shown.</italic>
            </italic>
          </attrib>
        </table-wrap-foot>
      </table-wrap>
      <p>Moreover, most of these cells driven by somatic mutations have been proposed to be associated with the progress of breast cancer. For example, in the TP53 mutation, 18 cells were identified (<xref rid="T2" ref-type="table">Table 2</xref>). It was proposed that type 1 T-helper (Th1) cells eradicated tumor mass by inducing cellular immunity, and type 2 T-helper (Th2) cells destroyed the tumor by inducing tumor necrosis (<xref rid="B21" ref-type="bibr">Nishimura et al., 1999</xref>). Macrophages M1 cells generate interleukin (IL)-12 and tumor necrosis factor with antitumor effects in breast cancer cells (<xref rid="B16" ref-type="bibr">Jeong et al., 2019</xref>). NK cells were reported to be critical immune components in controlling breast tumor growth and dissemination (<xref rid="B19" ref-type="bibr">Liu et al., 2019</xref>). For the cells driven by CDH1, CD4<sup>+</sup> central memory T cell (Tcm) was proposed to be negatively associated with recurrence-free survival in breast cancer (<xref rid="B8" ref-type="bibr">Deng et al., 2019</xref>). The above results indicate that the SMDIC method could effectively identify immune-related cells driven by somatic mutations and may help to facilitate the development of cancer immunotherapy.</p>
      <table-wrap id="T2" position="float">
        <label>TABLE 2</label>
        <caption>
          <p>The detailed information of immune cells driven by the TP53 gene mutation.</p>
        </caption>
        <table frame="hsides" rules="groups" cellspacing="5" cellpadding="5">
          <thead>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Cell</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Full name</td>
              <td valign="top" align="center" rowspan="1" colspan="1"><italic>p</italic>-value</td>
              <td valign="top" align="center" rowspan="1" colspan="1">FDR</td>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Th2 cells</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Type 2 T-helper cells</td>
              <td valign="top" align="center" rowspan="1" colspan="1">8.86E-13</td>
              <td valign="top" align="center" rowspan="1" colspan="1">4.16E-11</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Sebocytes</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Sebocytes</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.51E-09</td>
              <td valign="top" align="center" rowspan="1" colspan="1">3.55E-08</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Macrophages M1</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Macrophages M1</td>
              <td valign="top" align="center" rowspan="1" colspan="1">6.33E-09</td>
              <td valign="top" align="center" rowspan="1" colspan="1">9.91E-08</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Astrocytes</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Astrocytes</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.01E-07</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.19E-06</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Keratinocytes</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Keratinocytes</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.33E-07</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.02E-06</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Th1 cells</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Type 1 T-helper cells</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.58E-07</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.02E-06</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Macrophages</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Macrophages</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.00018</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0012</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Pericytes</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Pericytes</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.00035</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0020</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Tregs</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Regulatory T cells</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.00048</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0025</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">NK cells</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Natural killer cells</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.00054</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0025</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Epithelial cells</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Epithelial cells</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.00086</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0037</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Pdc</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Plasmacytoid dendritic cells</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0020</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0077</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Tgd cells</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Gamma delta T cells</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0021</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0077</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Pro-B cells</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Pro-B cells</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0026</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0089</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">CD8<sup>+</sup> naive T cells</td>
              <td valign="top" align="center" rowspan="1" colspan="1">CD8<sup>+</sup> naive T cells</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0040</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.013</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Melanocytes</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Melanocytes</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0052</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.015</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">DC</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Dendritic cells</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.016</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.042</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Plasma cells</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Plasma cells</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.016</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.042</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">CD8<sup>+</sup> Tem</td>
              <td valign="top" align="center" rowspan="1" colspan="1">CD8<sup>+</sup> effector memory T cells</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.017</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.043</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <sec id="S3.SS2">
      <title>Presentation of the Results</title>
      <p>We used the visualization function of the SMDIC package to demonstrate the analysis results of breast cancer. The detailed commands for these visualization functions are listed in <xref ref-type="supplementary-material" rid="SM1">Supplementary Material</xref>. The “plotwaterfall” function is applied to show the waterfall plot of mutation genes that drive immune cells (<xref ref-type="fig" rid="F2">Figure 2</xref>). To further analyze the correlation between these mutation genes, we used the “plotCoocMutex” function to plot the co-occurrence and mutual exclusivity plots (<xref ref-type="fig" rid="F3">Figure 3</xref>). TP53 and CDH1 show significant mutual exclusions (p &lt; 0.05). For a better display of the immune cell response triggered by somatic mutation, we used the “heatmapcell” function to plot a heat map to show the significant difference of cell abundance between gene mutation and non-mutation status. We selected the immune cells driven by TP53 as an example to show their heat map (<xref ref-type="fig" rid="F4">Figure 4</xref>). We can see that the heat maps of immune cells display two obviously different blocks between TP53 mutation and non-mutation samples. From the heat maps of immune cells driven by CDH1, a similar result was obtained (<xref ref-type="supplementary-material" rid="SM1">Supplementary Figure 1</xref>). We then used the “survcell” function to plot the Kaplan–Meier survival curves of patients classified into high- and low-risk groups using the median of the immune cell risk score (see Implementation section). The immune cells driven by TP53, CDH1, NBPF14, and OBSCN mutations were, respectively, selected to calculate the immune risk score for plotting Kaplan–Meier survival curves (<xref ref-type="fig" rid="F5">Figures 5A–D</xref>). It can be seen that immune cells driven by these mutations could be used as prognostic signatures. These results indicate that these mutations may be used as neoantigens for immunotherapy.</p>
      <fig id="F2" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Waterfall plot of mutation genes that drive immune cells in the GDC TCGA breast cancer dataset.</p>
        </caption>
        <graphic xlink:href="fcell-09-715275-g002"/>
      </fig>
      <fig id="F3" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>Co-occurrence and mutual exclusivity plots between mutation genes correlated with immune cells.</p>
        </caption>
        <graphic xlink:href="fcell-09-715275-g003"/>
      </fig>
      <fig id="F4" position="float">
        <label>FIGURE 4</label>
        <caption>
          <p>Heat map of cell abundance between TP53 mutation and non-mutation status.</p>
        </caption>
        <graphic xlink:href="fcell-09-715275-g004"/>
      </fig>
      <fig id="F5" position="float">
        <label>FIGURE 5</label>
        <caption>
          <p>Kaplan–Meier survival curves of patients with breast cancer classified into high- and low-risk groups based on the immune cells driven by <bold>(A)</bold> TP53, <bold>(B)</bold> CDH1, <bold>(C)</bold> NBPF14, and <bold>(D)</bold> OBSCN mutations, respectively.</p>
        </caption>
        <graphic xlink:href="fcell-09-715275-g005"/>
      </fig>
    </sec>
    <sec id="S3.SS3">
      <title>Robustness Analysis of the SMDIC Method</title>
      <p>We first tested if the immune cells driven by the specific somatic mutation had the same or similar prognostic value in different independent datasets. As the public cancer datasets with both genome and transcriptome are seldom, we used the mutation-specific immune cell signatures (see <italic>Implementation</italic> section) obtained from the TCGA breast cancer dataset to test their prognosis performance in independent gene expression datasets. We enrolled four independent datasets of breast cancer, namely, GSE1992 (<xref rid="B15" ref-type="bibr">Hu et al., 2006</xref>), GSE3143 (<xref rid="B4" ref-type="bibr">Bild et al., 2006</xref>), GSE1456 (<xref rid="B23" ref-type="bibr">Pawitan et al., 2005</xref>), and GSE7390 (<xref rid="B9" ref-type="bibr">Desmedt et al., 2007</xref>) datasets. The cell signature derived from TP53 mutation was firstly used to classify patients from four independent breast cancer expression datasets, respectively. For each independent dataset, the “exp2cell” was applied to convert gene expression profiles to cell abundance profiles, and the patients were divided into high-risk and low-risk groups based on the cell signature. Interestingly, the <italic>p</italic>-values of log-rank tests in these four datasets were all &lt; 0.05 (<xref ref-type="supplementary-material" rid="SM1">Supplementary Figures 2A–D</xref>). For the cell signature driven by CDH1, it was shown that the CDH1-specific cell signature could classify patients into high- and low-risk groups in three of the above four datasets (log-rank tests <italic>p</italic>-value &lt; 0.05, <xref ref-type="supplementary-material" rid="SM1">Supplementary Figures 3A–D</xref>). We also found that the cell signatures derived from NBPF14 and OBSCN mutations respectively obtained similar results (<xref ref-type="supplementary-material" rid="SM1">Supplementary Figures 4</xref>, <xref ref-type="supplementary-material" rid="SM1">5</xref>). These results confirmed that the mutation-driven immune cells could be used as prognostic signatures.</p>
      <p>We then tested if the SMDIC method is robust to missing data in the gene expression profiles. To do this, we performed data removal tests using the GDC TCGA breast cancer expression profiles. For the gene expression data, we randomly removed the genes in the original expression profiles from 5 to 20% at 5% intervals. For each data removal, we repeated the SMDIC method to identify somatic mutation-specific immune cells. We then compared these results with our original results. The mutation genes which trigger at least five immune cells, namely, TP53, CDH1, OBSCN, NF1 and NBPF14, were used to test how many significant immune cells are overlapped. With the data removal increasing, we found that the number of overlapped cells driven by each mutation gene fell slowly compared with the original data (<xref ref-type="fig" rid="F6">Figure 6</xref>). Moreover, 89% (17/19), 66% (8/12), 60% (3/5), and 50% (3/6) cells were shared with our original results for the TP53, CDH1, NBPF14, and OBSCN mutations, respectively, even after removal of up to 15% of the gene expression data. These results indicate that the SMDIC method is robust to missing data in the gene expression profiles.</p>
      <fig id="F6" position="float">
        <label>FIGURE 6</label>
        <caption>
          <p>Robustness analysis of the SMDIC method. The gene expression values were randomly removed from 5 to 20% at 5% intervals. For each removal, the overlapped number of the immune cells with the original results was calculated for the mutation genes which activate at least five immune cells.</p>
        </caption>
        <graphic xlink:href="fcell-09-715275-g006"/>
      </fig>
      <p>We further tested if the SMDIC method is robust to different methods for estimating abundance of immune cell infiltration. The default method for estimating cell abundance is xCell (<xref rid="B2" ref-type="bibr">Aran et al., 2017</xref>) in the package. We used an alternative ssGSEA estimated method (<xref rid="B25" ref-type="bibr">Senbabaoglu et al., 2016</xref>) to test if the SMDIC method could obtain consistent results. In the GDC TCGA breast cancer datasets, the SMDIC method identified 19 and 15 TP53 mutation-specific immune cell response in the xCell and ssGSEA cell abundance estimated methods (<xref rid="T2" ref-type="table">Table 2</xref> and <xref ref-type="supplementary-material" rid="SM1">Supplementary Table 1</xref>). There are only five overlapped immune cells, namely, type 1 T-helper (Th1) cell, type 2 T-helper (Th2) cell, gamma delta T cells (Tgd), regulatory T cells (Tregs), and NK cell. This is because xCell and ssGSEA use different cell estimated strategies and quantify different cell types. However, through calculating the Pearson correlation between xCell and ssGSEA values for relevant cell types driven by TP53 mutation, we observed relatively stronger levels of concordance (e.g., CD8<sup>+</sup> naive T cells vs. CD8 T cells, Pearson <italic>r</italic> = 0.31, <italic>p</italic>-value &lt; 1e-20; dendritic cells vs. activated dendritic cells, Pearson <italic>r</italic> = 0.53, <italic>p</italic>-value &lt; 1e-20) (<xref ref-type="supplementary-material" rid="SM1">Supplementary Table 2</xref>). These validation results show that our somatic mutation-driven immune cell method is robust to different cell abundance estimated methods.</p>
      <p>To further illustrate the applicability of our SMDIC method, we applied it to TCGA skin cutaneous melanoma (SKCM) data, which were downloaded from the GDC data portal (see text footnote 2). We inputted all the related data into the SMDIC package and performed the same operations like in the breast cancer data. The detailed results are listed in <xref ref-type="supplementary-material" rid="SM1">Supplementary Table 3</xref>. We found that some mutation cell associations identified by the method have been reported in the literature. For example, it has been proposed that deficiency of E3 ubiquitin ligase (ITCH) altered CD4 T-cell and B-cell responses in mice and humans (<xref rid="B11" ref-type="bibr">Field et al., 2020</xref>); HIVEP2 was found to play a crucial role in the control of Th2 cell differentiation by regulating NF-κB function, whose ortholog gene HIVEP3 may substitute for the function of HIVEP2 (<xref rid="B17" ref-type="bibr">Kimura et al., 2005</xref>). This indicates that the SMDIC method could identify mutation-specific cells in different cancers.</p>
    </sec>
  </sec>
  <sec id="S4">
    <title>Discussion</title>
    <p>Recently, a number of calculated methods have been developed to identify dysregulated genes and pathways in cancer using molecular omics data (genome or transcriptome) (<xref rid="B7" ref-type="bibr">Cheng et al., 2019</xref>; <xref rid="B12" ref-type="bibr">Han et al., 2020</xref>; <xref rid="B26" ref-type="bibr">Sheng et al., 2021</xref>). Moreover, some methods were proposed to prioritize cancer candidate drugs and prognostic markers (<xref rid="B13" ref-type="bibr">Han et al., 2018</xref>, <xref rid="B14" ref-type="bibr">2021</xref>; <xref rid="B10" ref-type="bibr">Di et al., 2019</xref>). However, the methods for identifying immune cells driven by specific somatic mutations are mainly based on biological experiments, and as far as we have known, no calculated tools could systematically identify mutation-specific immune cells.</p>
    <p>In the study, SMDIC R package is an automated, computationally fast, and efficient tool for exploring somatic mutation-driven immune cell response by integrating genome and transcriptome data. The users input the somatic mutation data and gene expression data with the same samples; the package will return the immune cells triggered by each mutation and provide visualization of results. Moreover, our package is not specifically designed for breast cancers and can be generally applicable for various cancer datasets with genomic and transcriptome data. The SMDIC tool was designed to identify somatic mutation-specific immune cells by integrating high-throughput genomic and transcriptome data, which may help to find neoantigens and facilitate the development of personalized immunotherapy to patients with cancers.</p>
  </sec>
  <sec sec-type="data-availability" id="S5">
    <title>Data Availability Statement</title>
    <p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/<xref ref-type="supplementary-material" rid="SM1">Supplementary Material</xref>.</p>
  </sec>
  <sec id="S6">
    <title>Ethics Statement</title>
    <p>Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.</p>
  </sec>
  <sec id="S7">
    <title>Author Contributions</title>
    <p>JH and YJ conceived and designed the study. BZ developed software. YY and XL analyzed the data and implemented the methodology. YJ revised the manuscript. JH drafted the manuscript. All authors read and agreed to the final version of the manuscript.</p>
  </sec>
  <sec sec-type="COI-statement" id="conf1">
    <title>Conflict of Interest</title>
    <p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
  </sec>
</body>
<back>
  <fn-group>
    <fn fn-type="financial-disclosure">
      <p><bold>Funding.</bold> This work was supported in part by the National Natural Science Foundation of China (grant nos. 62072145 and 81804158), the Natural Science Foundation of Heilongjiang Province (grant no. LH2019C042), and the University Student Innovation and Entrepreneurship Training Project of Heilongjiang Province (grant no. 201810226010).</p>
    </fn>
  </fn-group>
  <ack>
    <p>We thank the Training Center for Students Innovation and Entrepreneurship Education in Harbin Medical University.</p>
  </ack>
  <fn-group>
    <fn id="footnote1">
      <label>1</label>
      <p>
        <ext-link ext-link-type="uri" xlink:href="https://portal.gdc.cancer.gov/">https://portal.gdc.cancer.gov/</ext-link>
      </p>
    </fn>
  </fn-group>
  <sec id="S10" sec-type="supplementary material">
    <title>Supplementary Material</title>
    <p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fcell.2021.715275/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fcell.2021.715275/full#supplementary-material</ext-link></p>
    <supplementary-material content-type="local-data" id="SM1">
      <media xlink:href="Data_Sheet_1.doc">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="DS1">
      <media xlink:href="Data_Sheet_2.zip">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <ref-list>
    <title>References</title>
    <ref id="B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agupitan</surname><given-names>A. D.</given-names></name><name><surname>Neeson</surname><given-names>P.</given-names></name><name><surname>Williams</surname><given-names>S.</given-names></name><name><surname>Howitt</surname><given-names>J.</given-names></name><name><surname>Haupt</surname><given-names>S.</given-names></name><name><surname>Haupt</surname><given-names>Y.</given-names></name></person-group> (<year>2020</year>). <article-title>P53: a guardian of immunity becomes its saboteur through mutation.</article-title>
<source><italic>Int. J. Mol. Sci.</italic></source>
<volume>21</volume>:<issue>3452</issue>. <pub-id pub-id-type="doi">10.3390/ijms21103452</pub-id>
<?supplied-pmid 32414156?><pub-id pub-id-type="pmid">32414156</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aran</surname><given-names>D.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Butte</surname><given-names>A. J.</given-names></name></person-group> (<year>2017</year>). <article-title>xCell: digitally portraying the tissue cellular heterogeneity landscape.</article-title>
<source><italic>Genome Biol.</italic></source>
<volume>18</volume>:<issue>220</issue>.</mixed-citation>
    </ref>
    <ref id="B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y.</given-names></name><name><surname>Hochberg</surname><given-names>Y.</given-names></name></person-group> (<year>1995</year>). <article-title>Controlling the false discovery rate: a Practical and Powerful Approach to Multiple Testing.</article-title>
<source><italic>J. R. Stat. Soc. B</italic></source>
<volume>57</volume>
<fpage>289</fpage>–<lpage>300</lpage>. <pub-id pub-id-type="doi">10.1111/j.2517-6161.1995.tb02031.x</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bild</surname><given-names>A. H.</given-names></name><name><surname>Yao</surname><given-names>G.</given-names></name><name><surname>Chang</surname><given-names>J. T.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Potti</surname><given-names>A.</given-names></name><name><surname>Chasse</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Oncogenic pathway signatures in human cancers as a guide to targeted therapies.</article-title>
<source><italic>Nature</italic></source>
<volume>439</volume>
<fpage>353</fpage>–<lpage>357</lpage>. <pub-id pub-id-type="doi">10.1038/nature04296</pub-id>
<?supplied-pmid 16273092?><pub-id pub-id-type="pmid">16273092</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bindea</surname><given-names>G.</given-names></name><name><surname>Mlecnik</surname><given-names>B.</given-names></name><name><surname>Tosolini</surname><given-names>M.</given-names></name><name><surname>Kirilovsky</surname><given-names>A.</given-names></name><name><surname>Waldner</surname><given-names>M.</given-names></name><name><surname>Obenauf</surname><given-names>A. C.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.</article-title>
<source><italic>Immunity</italic></source>
<volume>39</volume>
<fpage>782</fpage>–<lpage>795</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2013.10.003</pub-id>
<?supplied-pmid 24138885?><pub-id pub-id-type="pmid">24138885</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>D. S.</given-names></name><name><surname>Mellman</surname><given-names>I.</given-names></name></person-group> (<year>2017</year>). <article-title>Elements of cancer immunity and the cancer-immune set point.</article-title>
<source><italic>Nature</italic></source>
<volume>541</volume>
<fpage>321</fpage>–<lpage>330</lpage>. <pub-id pub-id-type="doi">10.1038/nature21349</pub-id>
<?supplied-pmid 28102259?><pub-id pub-id-type="pmid">28102259</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>P.</given-names></name><name><surname>Zhou</surname><given-names>W.</given-names></name><name><surname>Luo</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Computational Methods for Identifying Similar Diseases.</article-title>
<source><italic>Mol. Ther. Nucleic Acids</italic></source>
<volume>18</volume>
<fpage>590</fpage>–<lpage>604</lpage>. <pub-id pub-id-type="doi">10.1016/j.omtn.2019.09.019</pub-id>
<?supplied-pmid 31678735?><pub-id pub-id-type="pmid">31678735</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>L.</given-names></name><name><surname>Lu</surname><given-names>D.</given-names></name><name><surname>Bai</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Bu</surname><given-names>H.</given-names></name><name><surname>Zheng</surname><given-names>H.</given-names></name></person-group> (<year>2019</year>). <article-title>Immune Profiles of Tumor Microenvironment and Clinical Prognosis among Women with Triple-Negative Breast Cancer.</article-title>
<source><italic>Cancer Epidemiol. Biomarkers Prev.</italic></source>
<volume>28</volume>
<fpage>1977</fpage>–<lpage>1985</lpage>. <pub-id pub-id-type="doi">10.1158/1055-9965.epi-19-0469</pub-id>
<?supplied-pmid 31533938?><pub-id pub-id-type="pmid">31533938</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desmedt</surname><given-names>C.</given-names></name><name><surname>Piette</surname><given-names>F.</given-names></name><name><surname>Loi</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Lallemand</surname><given-names>F.</given-names></name><name><surname>Haibe-Kains</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series.</article-title>
<source><italic>Clin. Cancer Res.</italic></source>
<volume>13</volume>
<fpage>3207</fpage>–<lpage>3214</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.ccr-06-2765</pub-id>
<?supplied-pmid 17545524?><pub-id pub-id-type="pmid">17545524</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di</surname><given-names>J.</given-names></name><name><surname>Zheng</surname><given-names>B.</given-names></name><name><surname>Kong</surname><given-names>Q.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities.</article-title>
<source><italic>Mol. Oncol.</italic></source>
<volume>13</volume>
<fpage>2259</fpage>–<lpage>2277</lpage>. <pub-id pub-id-type="doi">10.1002/1878-0261.12564</pub-id>
<?supplied-pmid 31408580?><pub-id pub-id-type="pmid">31408580</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Field</surname><given-names>N. S.</given-names></name><name><surname>Moser</surname><given-names>E. K.</given-names></name><name><surname>Oliver</surname><given-names>P. M.</given-names></name></person-group> (<year>2020</year>). <article-title>Itch regulation of innate and adaptive immune responses in mice and humans.</article-title>
<source><italic>J. Leukoc. Biol.</italic></source>
<volume>108</volume>
<fpage>353</fpage>–<lpage>362</lpage>. <pub-id pub-id-type="doi">10.1002/jlb.3mir0320-272r</pub-id>
<?supplied-pmid 32356405?><pub-id pub-id-type="pmid">32356405</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>J.</given-names></name><name><surname>Han</surname><given-names>X.</given-names></name><name><surname>Kong</surname><given-names>Q.</given-names></name><name><surname>Cheng</surname><given-names>L.</given-names></name></person-group> (<year>2020</year>). <article-title>psSubpathway: a software package for flexible identification of phenotype-specific subpathways in cancer progression.</article-title>
<source><italic>Bioinformatics</italic></source>
<volume>36</volume>
<fpage>2303</fpage>–<lpage>2305</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btz894</pub-id>
<?supplied-pmid 31821408?><pub-id pub-id-type="pmid">31821408</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>C.</given-names></name><name><surname>Zheng</surname><given-names>B.</given-names></name><name><surname>Jiang</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Inference of patient-specific subpathway activities reveals a functional signature associated with the prognosis of patients with breast cancer.</article-title>
<source><italic>J. Cell Mol. Med.</italic></source>
<volume>22</volume>
<fpage>4304</fpage>–<lpage>4316</lpage>. <pub-id pub-id-type="doi">10.1111/jcmm.13720</pub-id>
<?supplied-pmid 29971923?><pub-id pub-id-type="pmid">29971923</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>X.</given-names></name><name><surname>Kong</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Cheng</surname><given-names>L.</given-names></name><name><surname>Han</surname><given-names>J.</given-names></name></person-group> (<year>2021</year>). <article-title>SubtypeDrug: a software package for prioritization of candidate cancer subtype-specific drugs.</article-title>
<source><italic>Bioinformatics</italic></source>
<pub-id pub-id-type="doi">10.1093/bioinformatics/btab011</pub-id> [Epub Online ahead of print]. <?supplied-pmid 33459772?><pub-id pub-id-type="pmid">33459772</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Fan</surname><given-names>C.</given-names></name><name><surname>Oh</surname><given-names>D. S.</given-names></name><name><surname>Marron</surname><given-names>J. S.</given-names></name><name><surname>He</surname><given-names>X.</given-names></name><name><surname>Qaqish</surname><given-names>B. F.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>The molecular portraits of breast tumors are conserved across microarray platforms.</article-title>
<source><italic>BMC Genomics</italic></source>
<volume>7</volume>:<issue>96</issue>. <pub-id pub-id-type="doi">10.1186/1471-2164-7-96</pub-id>
<?supplied-pmid 16643655?><pub-id pub-id-type="pmid">16643655</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>H.</given-names></name><name><surname>Hwang</surname><given-names>I.</given-names></name><name><surname>Kang</surname><given-names>S. H.</given-names></name><name><surname>Shin</surname><given-names>H. C.</given-names></name><name><surname>Kwon</surname><given-names>S. Y.</given-names></name></person-group> (<year>2019</year>). <article-title>Tumor-Associated Macrophages as Potential Prognostic Biomarkers of Invasive Breast Cancer.</article-title>
<source><italic>J. Breast Cancer</italic></source>
<volume>22</volume>
<fpage>38</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.4048/jbc.2019.22.e5</pub-id>
<?supplied-pmid 30941232?><pub-id pub-id-type="pmid">30941232</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>M. Y.</given-names></name><name><surname>Hosokawa</surname><given-names>H.</given-names></name><name><surname>Yamashita</surname><given-names>M.</given-names></name><name><surname>Hasegawa</surname><given-names>A.</given-names></name><name><surname>Iwamura</surname><given-names>C.</given-names></name><name><surname>Watarai</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Regulation of T helper type 2 cell differentiation by murine Schnurri-2.</article-title>
<source><italic>J. Exp. Med.</italic></source>
<volume>201</volume>
<fpage>397</fpage>–<lpage>408</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20040733</pub-id>
<?supplied-pmid 15699073?><pub-id pub-id-type="pmid">15699073</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Yao</surname><given-names>Q.</given-names></name><name><surname>Xiao</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Ma</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>APC/Cdh1 targets PECAM-1 for ubiquitination and degradation in endothelial cells.</article-title>
<source><italic>J. Cell Physiol.</italic></source>
<volume>235</volume>
<fpage>2521</fpage>–<lpage>2531</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.29156</pub-id>
<?supplied-pmid 31489637?><pub-id pub-id-type="pmid">31489637</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Dhar</surname><given-names>P.</given-names></name><name><surname>Wu</surname><given-names>J. D.</given-names></name></person-group> (<year>2019</year>). <article-title>NK Cell Plasticity in Cancer.</article-title>
<source><italic>J. Clin. Med.</italic></source>
<volume>8</volume>:<issue>1492</issue>. <pub-id pub-id-type="doi">10.3390/jcm8091492</pub-id>
<?supplied-pmid 31546818?><pub-id pub-id-type="pmid">31546818</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>A. M.</given-names></name><name><surname>Liu</surname><given-names>C. L.</given-names></name><name><surname>Green</surname><given-names>M. R.</given-names></name><name><surname>Gentles</surname><given-names>A. J.</given-names></name><name><surname>Feng</surname><given-names>W.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Robust enumeration of cell subsets from tissue expression profiles.</article-title>
<source><italic>Nat. Methods</italic></source>
<volume>12</volume>
<fpage>453</fpage>–<lpage>457</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.3337</pub-id>
<?supplied-pmid 25822800?><pub-id pub-id-type="pmid">25822800</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>T.</given-names></name><name><surname>Iwakabe</surname><given-names>K.</given-names></name><name><surname>Sekimoto</surname><given-names>M.</given-names></name><name><surname>Ohmi</surname><given-names>Y.</given-names></name><name><surname>Yahata</surname><given-names>T.</given-names></name><name><surname>Nakui</surname><given-names>M.</given-names></name><etal/></person-group> (<year>1999</year>). <article-title>Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo.</article-title>
<source><italic>J. Exp. Med.</italic></source>
<volume>190</volume>
<fpage>617</fpage>–<lpage>627</lpage>. <pub-id pub-id-type="doi">10.1084/jem.190.5.617</pub-id>
<?supplied-pmid 10477547?><pub-id pub-id-type="pmid">10477547</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oshi</surname><given-names>M.</given-names></name><name><surname>Asaoka</surname><given-names>M.</given-names></name><name><surname>Tokumaru</surname><given-names>Y.</given-names></name><name><surname>Angarita</surname><given-names>F. A.</given-names></name><name><surname>Yan</surname><given-names>L.</given-names></name><name><surname>Matsuyama</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Abundance of Regulatory T Cell (Treg) as a Predictive Biomarker for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.</article-title>
<source><italic>Cancers</italic></source>
<volume>12</volume>:<issue>3038</issue>. <pub-id pub-id-type="doi">10.3390/cancers12103038</pub-id>
<?supplied-pmid 33086518?><pub-id pub-id-type="pmid">33086518</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawitan</surname><given-names>Y.</given-names></name><name><surname>Bjohle</surname><given-names>J.</given-names></name><name><surname>Amler</surname><given-names>L.</given-names></name><name><surname>Borg</surname><given-names>A. L.</given-names></name><name><surname>Egyhazi</surname><given-names>S.</given-names></name><name><surname>Hall</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts.</article-title>
<source><italic>Breast Cancer Res.</italic></source>
<volume>7</volume>
<fpage>R953</fpage>–<lpage>64</lpage>.<pub-id pub-id-type="pmid">16280042</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robbins</surname><given-names>P. F.</given-names></name><name><surname>Lu</surname><given-names>Y. C.</given-names></name><name><surname>El-Gamil</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>Y. F.</given-names></name><name><surname>Gross</surname><given-names>C.</given-names></name><name><surname>Gartner</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells.</article-title>
<source><italic>Nat. Med.</italic></source>
<volume>19</volume>
<fpage>747</fpage>–<lpage>752</lpage>. <pub-id pub-id-type="doi">10.1038/nm.3161</pub-id>
<?supplied-pmid 23644516?><pub-id pub-id-type="pmid">23644516</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senbabaoglu</surname><given-names>Y.</given-names></name><name><surname>Gejman</surname><given-names>R. S.</given-names></name><name><surname>Winer</surname><given-names>A. G.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Van Allen</surname><given-names>E. M.</given-names></name><name><surname>De Velasco</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.</article-title>
<source><italic>Genome Biol.</italic></source>
<volume>17</volume>:<issue>231</issue>.</mixed-citation>
    </ref>
    <ref id="B26">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheng</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Qiu</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>CNA2Subpathway: identification of dysregulated subpathway driven by copy number alterations in cancer.</article-title>
<source><italic>Brief Bioinform</italic></source>
<volume>2021</volume>:<issue>bbaa413</issue>. <pub-id pub-id-type="doi">10.1093/bib/bbaa413</pub-id>
<?supplied-pmid 33423051?><pub-id pub-id-type="pmid">33423051</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname><given-names>E.</given-names></name><name><surname>Turcotte</surname><given-names>S.</given-names></name><name><surname>Gros</surname><given-names>A.</given-names></name><name><surname>Robbins</surname><given-names>P. F.</given-names></name><name><surname>Lu</surname><given-names>Y. C.</given-names></name><name><surname>Dudley</surname><given-names>M. E.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.</article-title>
<source><italic>Science</italic></source>
<volume>344</volume>
<fpage>641</fpage>–<lpage>645</lpage>. <pub-id pub-id-type="doi">10.1126/science.1251102</pub-id>
<?supplied-pmid 24812403?><pub-id pub-id-type="pmid">24812403</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tusher</surname><given-names>V. G.</given-names></name><name><surname>Tibshirani</surname><given-names>R.</given-names></name><name><surname>Chu</surname><given-names>G.</given-names></name></person-group> (<year>2001</year>). <article-title>Significance analysis of microarrays applied to the ionizing radiation response.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U. S. A.</italic></source>
<volume>98</volume>
<fpage>5116</fpage>–<lpage>5121</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.091062498</pub-id>
<?supplied-pmid 11309499?><pub-id pub-id-type="pmid">11309499</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>F.</given-names></name><name><surname>Kim</surname><given-names>D. K.</given-names></name><name><surname>Nakagawa</surname><given-names>H.</given-names></name><name><surname>Hayashi</surname><given-names>S.</given-names></name><name><surname>Imoto</surname><given-names>S.</given-names></name><name><surname>Stein</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Quantifying immune-based counterselection of somatic mutations.</article-title>
<source><italic>PLoS Genet.</italic></source>
<volume>15</volume>:<issue>e1008227</issue>. <pub-id pub-id-type="doi">10.1371/journal.pgen.1008227</pub-id>
<?supplied-pmid 31344031?><pub-id pub-id-type="pmid">31344031</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
